<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015127</url>
  </required_header>
  <id_info>
    <org_study_id>9161.5</org_study_id>
    <nct_id>NCT05015127</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbour BioMed (Guangzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbour BioMed (Guangzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: To preliminarily evaluate the efficacy of the treatment regimen of HBM9161&#xD;
      680 mg administered subcutaneously weekly and sequentially every other week for 12 weeks in&#xD;
      Chinese patients with active moderate to severe TED.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind and placebo-controlled study. The&#xD;
      investigational drug is HBM9161 injection, with the indication of TED. Subjects will be&#xD;
      randomized to treatment group I, treatment group II, or placebo group. Subjects in treatment&#xD;
      group 1 will receive HBM9161 680 mg subcutaneously once weekly (qw) for 12 doses; Subjects in&#xD;
      treatment group 2 will receive HBM9161 680 mg subcutaneously once weekly (qw) for 6 doses,&#xD;
      followed by HBM9161 680 mg subcutaneously once every two weeks (q2w) for 3 doses; Subjects in&#xD;
      placebo group will receive placebo subcutaneously once weekly (qw) for 12 doses. After the&#xD;
      12-week dosing period, there will be a 5-week follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proptosis responder rates of the treatment groups and placebo group at Week 12</measure>
    <time_frame>At week 12</time_frame>
    <description>Proptosis responder rates of the treatment groups and placebo group at Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with a CAS value of 0 or 1 in the study eye</measure>
    <time_frame>At week 6 and week 12</time_frame>
    <description>The percentage of subjects with a CAS value of 0 or 1 in the study eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from Baseline in proptosis measurement in the study eye</measure>
    <time_frame>At week 6 and week 12</time_frame>
    <description>The change from Baseline in proptosis measurement in the study eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite responder rate</measure>
    <time_frame>At week 6 and week 12</time_frame>
    <description>Composite responder rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diplopia response rate</measure>
    <time_frame>At week 6 and week 12</time_frame>
    <description>Diplopia response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire visual function score and psychosocial function score</measure>
    <time_frame>At week 6 and week 12</time_frame>
    <description>The change from baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire visual function score and psychosocial function score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in proptosis responder rate over time</measure>
    <time_frame>At week 6 and week 12</time_frame>
    <description>The changes in proptosis responder rate over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in quantitative measurement of orbital structures by MRI, including exophthalmos values, fatty tissue thickness of inner side in eye balls, thickness of extraocular muscles. All the above parameters will be measured in millimeter</measure>
    <time_frame>At week 12</time_frame>
    <description>The change from baseline in quantitative measurement of orbital structures by MRI, including exophthalmos values, fatty tissue thickness of inner side in eye balls, thickness of extraocular muscles. All the above parameters will be measured in millimeter</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Thyroid Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>HBM9161 680 mg qw</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection; HBM9161 680 mg qw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBM9161 680 mg qw by q2w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection; HBM9161 680 mg qw by q2w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection; Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HBM9161 680 mg qw</intervention_name>
    <description>HBM9161 680 mg qw</description>
    <arm_group_label>HBM9161 680 mg qw</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HBM9161 680 mg qw by q2w</intervention_name>
    <description>HBM9161 680 mg qw by q2w</description>
    <arm_group_label>HBM9161 680 mg qw by q2w</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent form.&#xD;
&#xD;
          2. Male or female ≥ 18 years of age.&#xD;
&#xD;
          3. Active TED associated with a clinical diagnosis of Graves' disease or Hashimoto's&#xD;
             thyroiditis with CAS ≥ 3 at the screening visit and baseline (both on a 7-item scale)&#xD;
             in the eye with the most severe proptosis.&#xD;
&#xD;
          4. The active period of TED starts within 9 months prior to screening visit&#xD;
&#xD;
          5. Positive anti-TSHR antibody at screening visit.&#xD;
&#xD;
          6. Subject is willing and able to receive treatment and complete corresponding&#xD;
             assessments as required by the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other uncontrolled concurrent diseases&#xD;
&#xD;
          2. Serious TED requiring surgery or radiotherapy&#xD;
&#xD;
          3. Suffer from autoimmune diseases or ophthalmic conditions other than TED that, in the&#xD;
             opinion of the investigator, would impact the assessment of the study drug&#xD;
&#xD;
          4. No significant laboratory abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huifang Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huifang Zhou</last_name>
    <phone>+86 13661901886</phone>
    <email>fangzzfang@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Sun</last_name>
    <phone>+86 18516204866</phone>
    <email>sophiasj@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huifang Zhou</last_name>
      <phone>+8613661901886</phone>
      <email>fangzzfang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TED</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

